CVS Health Corporation's 2022 Second Quarter Update: Emerging Trends and Uncertainties

Strategic Insights -

As a leading diversified health solutions company, CVS Health Corporation has continued to navigate an increasingly complex and dynamic healthcare landscape. In its latest update, the company highlights key trends and uncertainties specific to its reportable segments, including the impact of COVID-19, changes in public policy and regulations, and shifts in consumer behavior.

Key Takeaways:

  • The Health Care Benefits segment is expected to continue to benefit from Medicare and Commercial membership growth, partially offset by the impact of the International Health Care Benefits Renewal Rights Asset sale.
  • The Pharmacy Services segment is expected to benefit from the Company's ability to drive further improvements in purchasing economics and strong pharmacy network volume, partially offset by continued client price improvements and regulation of pharmacy pricing.
  • The Retail/LTC segment is expected to continue to benefit from increased prescription volume and improved generic drug purchasing, partially offset by continued pharmacy reimbursement pressure and incremental operating expenses associated with the Company's minimum wage investment.
  • The Company expects to see continued strength in front store sales, including sales of OTC test kits, in 2022.
  • The Company is expected to benefit from the continuation of its enterprise-wide cost savings initiatives, which aim to reduce the Company's operating cost structure in a way that improves the consumer experience and is sustainable.

Statistics:

  • As of June 30, 2022, the Retail/LTC segment operated more than 9,000 retail locations, more than 1,100 MinuteClinic locations, and online retail pharmacy websites, LTC pharmacies, and on-site pharmacies.
  • The Company serves an estimated 35 million people through traditional, voluntary, and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan.
  • The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC, and Corporate/Other.
  • The Company's adjusted operating income excludes the impact of amortization of intangible assets and other items that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance.

Sources:

  • "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") Overview of Business" (COMTEX, August 3, 2022)
  • "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") Overview of the Health Care Benefits Segment" (COMTEX, August 3, 2022)
  • "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") Overview of the Pharmacy Services Segment" (COMTEX, August 3, 2022)
  • "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") Overview of the Retail/LTC Segment" (COMTEX, August 3, 2022)
  • "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") Overview of Current Trends" (COMTEX, August 3, 2022)